A number of other equities research analysts also recently issued reports on the stock. Roth Capital assumed coverage on shares of Bluebird Bio in a research report on Thursday, September 22nd. They issued a buy rating and a $87.00 target price for the company. Goldman Sachs Group Inc. upgraded shares of Bluebird Bio from a buy rating to a conviction-buy rating and set a $135.00 target price for the company in a research report on Thursday, September 15th. BTIG Research reiterated a buy rating and issued a $72.00 target price on shares of Bluebird Bio in a research report on Sunday, September 11th. Cowen and Company restated an outperform rating on shares of Bluebird Bio in a report on Friday, September 9th. Finally, Leerink Swann restated a buy rating on shares of Bluebird Bio in a report on Friday, September 9th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $89.17.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 72.97 on Thursday. The stock’s market capitalization is $2.71 billion. The stock’s 50 day moving average is $58.81 and its 200 day moving average is $48.79. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $106.95.
Bluebird Bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. During the same quarter in the previous year, the company earned ($1.57) EPS. The firm’s quarterly revenue was down 68.6% compared to the same quarter last year. Analysts anticipate that Bluebird Bio will post ($6.18) EPS for the current fiscal year.
In other news, insider Eric Sullivan sold 2,807 shares of Bluebird Bio stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total transaction of $126,427.28. Following the sale, the insider now directly owns 4,656 shares in the company, valued at approximately $209,706.24. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Davidson sold 1,000 shares of Bluebird Bio stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the sale, the insider now owns 10,600 shares in the company, valued at $477,848. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the stock. Seven Eight Capital LLC acquired a new stake in shares of Bluebird Bio during the first quarter valued at $108,000. Legal & General Group Plc raised its stake in shares of Bluebird Bio by 31.6% in the first quarter. Legal & General Group Plc now owns 2,895 shares of the company’s stock valued at $123,000 after buying an additional 695 shares during the period. Quantbot Technologies LP raised its stake in shares of Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock valued at $123,000 after buying an additional 2,312 shares during the period. BlackRock Inc. raised its stake in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in shares of Bluebird Bio by 25.3% in the second quarter. Teacher Retirement System of Texas now owns 5,114 shares of the company’s stock valued at $221,000 after buying an additional 1,034 shares during the period.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.